Vincere Biosciences

Executive Summary

Vincere Biosciences is a Boston-based biotech developing small-molecule inhibitors of USP30, a deubiquitinase that regulates mitochondrial quality control. Founded in 2018, the company leverages a proprietary virtual cell platform integrating human genetics and computational biology to identify targets for age-related diseases. Its lead program targets Parkinson's disease and kidney disease, where mitochondrial dysfunction plays a key role. By inhibiting USP30, Vincere aims to enhance mitophagy and restore cellular homeostasis, offering a potentially disease-modifying approach. The company is privately held and has advanced its lead candidate through preclinical studies, with plans to file an IND in the near term.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data in Parkinson's disease model60% success
• H1 2027IND filing for lead USP30 inhibitor50% success
• TBDPotential strategic partnership or licensing deal40% success